The management of serous papillary uterine cancer
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Cancer Research,Oncology
Reference37 articles.
1. Rare uterine tumors;Acharya;Lancet Oncol,2005
2. Endometrial cancer: asymptomatic endometrial findings characteristics of postmenopausal endometrial cancer;Marchetti;Eur J Gynaecol Oncol,2005
3. Uterine papillary serous carcinoma: what have we learned over the past quarter century?;Goff;Gynecol Oncol,2005
4. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas;Shedden;Clin Cancer Res,2005
5. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer;Maxwell;Clin Cancer Res,2005
Cited by 44 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Advanced uterine papillary serous cancer: Could there be a role for newer targeted therapeutic approaches or immune checkpoint inhibitors?;Journal of Oncology Pharmacy Practice;2021-05-13
2. Cutaneous and Inguinal Lymph Nodes Metastases Disseminated from an Endometrial Serous Carcinoma - Case Report and Literature Review;Chirurgia;2021
3. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis;Clinical Cancer Research;2020-06-29
4. Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma;International Journal of Gynecologic Cancer;2018-09
5. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu;Journal of Clinical Oncology;2018-07-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3